HIV vaccine nears clinical trial following new findings

A promising vaccine that clears an HIV-like virus from monkeys is closer to human testing after a new, weakened version of the vaccine has been shown to provide similar protection as its original version. A pair of papers published July 17 in Science Translational Medicine describe how the vaccine - which uses a form of the common herpes virus cytomegalovirus, or CMV - was live-attenuated, or weakened so CMV couldn't spread as easily. The new version still managed to eliminate SIV, the monkey version of HIV, in 59 percent of vaccinated rhesus macaques. That result is similar to earlier findings involving the vaccine's original, non-attenuated version. The immunity generated by the attenuated vaccine was also long-lasting, as nine of 12 vaccinated monkeys could still fight off SIV infection three years later.

Having an attenuated version of the vaccine is key to being potentially able to use it in humans. No vaccines use non-attenuated live viruses due to safety concerns. Though humans are often infected with CMV without any trouble, the virus can wreak havoc on those with weakened immune systems such as people with organ transplants. It's also dangerous for pregnant women, as it can cause congenital defects such as hearing loss and microcephaly in babies.

"This research, using rhesus CMV, provides potentially important insights into the design of a human CMV-based HIV vaccine," said Klaus Früh, Ph.D., a corresponding author on one of the papers. "We significantly attenuated CMV and still got the same type of immune responses as with the wild version of this vaccine."

"These papers are important because they recapitulate the previously reported unique CMV vector efficacy with a genetically modified vector that is highly attenuated and therefore potentially safer for clinical use," said Louis Picker, M.D., a corresponding author on both papers. "In addition, this new work demonstrates most vaccinated rhesus macaques that are protected against SIV can also be protected against a second challenge years after initial vaccination. This is a level of durability that would be very important for a human HIV vaccine".

Picker and Früh are professors at OHSU's Vaccine & Gene Therapy Institute and affiliated faculty in the OHSU School of Medicine's department for molecular microbiology and immunology.

The CMV vaccine platform has been licensed by Vir Biotechnology, Inc., of San Francisco, which plans to lead a clinical trial with a human version of the CMV-based HIV vaccine. The same platform is also expected to be used for vaccines being developed to fight tuberculosis.

Emily E Marshall, Daniel Malouli, Scott G Hansen, Roxanne M Gilbride, Colette M Hughes, Abigail B Ventura, Emily Ainslie, Andrea N Selseth, Julia C Ford, David Burke, Caraig N Kreklywich, Jennie Womack, Alfred W Legasse, Michael K Axthelm, Chrisoph Kahl, Daniel Streblow, Paul T Edlefsen, Louis J Picker, Klaus Früh.
Enhancing safety of cytomegalovirus-based vaccine vectors by engaging host intrinsic immunity.
Science Translational Medicine, July 17, 2019. doi: 10.1126/scitranslmed.aaw2603.

Scott G Hansen, Emily E. Marshall, Daniel Malouli, Abigail B Ventura, Colette M Hughes, Emily Ainslie, Julia C Ford, David Morrow, Roxanne M Gilbride, Jin Y Bae, Alfred W Legasse, Kelli Oswald, Rebecca Shoemaker, Brian Berkemeier, William J Bosche, Michael Hull, Jennie Womack, Jason Shao, Paul T Edlefsen, Jason S Reed, Ben J Burwitz, Jonah B Sacha, Michael K Axthelm, Klaus Früh, Jeffery D Lifson, Louis J Picker.
A live-attenuated RhCMV/SIV vaccine shows long-term efficacy against heterologous SIV challenge.
Science Translational Medicine, July 17, 2019. doi: 10.1126/scitranslmed.aaw2607.

Most Popular Now

Roche's COVID-19 antibody test receives FDA Emerge…

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) (1) for its new Elecsys® Ant...

Pfizer and BioNTech dose first participants in the…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced that the first participants have been dosed in the U.S. in the Phase 1/2 clinical trial for the BNT162 va...

Johnson & Johnson announces collaboration to e…

Johnson & Johnson (the Company) (NYSE: JNJ) announced a collaboration between the Janssen Pharmaceutical Companies of Johnson & Johnson and Emergent BioSolutions, Inc. to...

Researchers urge clinical trial of blood pressure …

Researchers in the Ludwig Center at the Johns Hopkins Kimmel Cancer Center report they have identified a drug treatment that could - if given early enough - potentially r...

Official COVID-19 deaths underestimate the full im…

According to a study by Charité - Universitätsmedizin Berlin, the northern Italian city of Nembro recorded more deaths during March 2020 than between January and December...

Early indicators of vaccine efficacy

Ludwig-Maximilians-Universität (LMU) in Munich researchers have shown that a specific class of immune cells in the blood induced by vaccination is an earlier indicator of...

Arthritis drug may improve respiratory function in…

A small study in Greece found that the clinically approved anti-inflammatory drug anakinra, used to treat rheumatoid arthritis, improved respiratory function in patients ...

Local climate unlikely to drive the early COVID-19…

Local variations in climate are not likely to dominate the first wave of the COVID-19 pandemic, according to a Princeton University study published May 18 in the journal ...

Frankfurt researchers discover potential targets f…

A team of biochemists and virologists at Goethe University and the Frankfurt University Hospital were able to observe how human cells change upon infection with SARS-CoV-...

AstraZeneca advances response to global COVID-19 c…

AstraZeneca is advancing its ongoing response to address the unprecedented challenges of COVID-19, collaborating with a number of countries and multilateral organisations...

Antibody neutralizes SARS and COVID-19 coronavirus…

An antibody first identified in a blood sample from a patient who recovered from Severe Acute Respiratory Syndrome in 2003 inhibits related coronaviruses, including the c...

Vitamin D linked to low virus death rate

A new study has found an association between low average levels of vitamin D and high numbers of COVID-19 cases and mortality rates across 20 European countries. The r...